TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06091904
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Study: NCT06091904
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
Study: NCT05024513
Drug: oxaliplatin and 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.
Study: NCT05644873
Drug: control group saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study: NCT06513208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline as placebo
Study: NCT00000628
Drug: L-697,661
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04767711
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glucocorticoid 25 mg daily for 7 days.
Study: NCT04608786
Drug: ZKAB001 5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
Study: NCT04608786
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
Study: NCT04930354
Drug: ECP-1014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
Study: NCT05663060
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Formula
Study: NCT05595109
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice.
Study: NCT05595109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
Study: NCT04637529
Drug: S (+) - Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S (+) - Ibuprofen + placebo of Ibuvix®
Study: NCT04637529
Drug: Ibuvix® - ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuvix® + placebo of S(+) - Ibuprofen
Study: NCT04825743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
Study: NCT05437419
Drug: TCK-276
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
Study: NCT05437419
Drug: TCK-276 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
Study: NCT05391776
Drug: TST002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
Study: NCT05391776
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
Study: NCT05248841
Drug: US-Lantus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
Study: NCT05456256
Drug: LP-300
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Study: NCT04696146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline placebo
Study: NCT04996667
Drug: inhaled nitric oxide (iNO)
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.
Study: NCT05000983
Drug: PluroGel
Normalized name: PLUROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Study: NCT05000983
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Study: NCT05204836
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg / 100 mL intravenous infusion
Study: NCT05204836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL intravenous infusion
Study: NCT05595681
Drug: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO.
Study: NCT04220008
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05878574
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
Study: NCT05173090
Drug: Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
Study: NCT06547736
Drug: SHR-A2102 or/and HRS-4642
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT06547736
Drug: SHR-A1811 or/and HRS-4642
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT06696573
Drug: Prophylactic NSAID Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive a prophylactic dose of a non-steroidal anti-inflammatory drug (NSAID) prior to the onset of pain during medical abortion procedures for pregnancies between 13 and 22 weeks. The intervention aims to reduce pain intensity throughout the process. The NSAID administration involves a specific dosage and schedule, adhering to safety guidelines and monitored for potential side effects.
Study: NCT06696573
Drug: On-Demand NSAID Administration
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive a non-steroidal anti-inflammatory drug (NSAID), such as Ibuprofen, in oral tablet form at a dose of 400 mg. The drug will be administered as needed when participants report experiencing pain during the medical abortion process for pregnancies between 13 and 22 weeks. The goal of this intervention is to provide pain relief in response to individual needs, with administration and dosage adjusted as clinically indicated. Monitoring will occur to assess the efficacy, safety, and patient response to the on-demand approach.
Study: NCT05074056
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will administer intraoperative ketorlac.
Study: NCT06697899
Drug: TGRX-678
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are given TGRX-678 orally at 240 mg
Study: NCT05695495
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT04836533
Drug: Experimental: Open-label antidepressant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
Study: NCT06084364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular injection with saline
Study: NCT05448456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% normal saline
Study: NCT05009901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily for 8 weeks
Study: NCT05600075
Drug: microneedling with topical human insulin solution.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Study: NCT06040541
Drug: RMC-9805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT06040541
Drug: RMC-6236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets
Study: NCT05036135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via dry powder inhalation
Study: NCT05063201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Study: NCT05221892
Drug: Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to be taken 30 minutes before each of 4 trips.
Study: NCT06214403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline Cellulose
Study: NCT06546839
Drug: SPSIPB blcok
Approvals — FDA: no, EMA: no, PMDA: no
Description: A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
Study: NCT06546839
Drug: Postoperative analgesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT05247203
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
Study: NCT04778592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06162442
Drug: Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria.
Study: NCT06701305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injectable solution
Study: NCT06701305
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT05790694
Drug: HBM9378 (SKB378) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 225 mg (1.5 mL)/vial
Study: NCT05790694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 225 mg (1.5 mL)/vial
Study: NCT06033287
Drug: Different treatment regimens following progression on CDK4/6 inhibitors.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
Study: NCT05757531
Drug: [¹⁴C]-LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05485558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
Study: NCT05357040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT05162586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to Enpatoran up to 24 weeks.
Study: NCT05886478
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: As this is an observational study, no intervention will be administered.
Study: NCT06486883
Drug: CDK4/6i plus ET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
Study: NCT04863794
Drug: RO7248824
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
Study: NCT06050980
Drug: HSK40118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, QD
Study: NCT04927221
Drug: DC371739 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one of 5 dose levels of DC371739 administered as single oral doses.
Study: NCT04927221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally administered as comparison
Study: NCT05587283
Drug: Experimental: Low dose LABTHERA-001 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.
Study: NCT05587283
Drug: Experimental: Medium dose LABTHERA-001 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.
Study: NCT04713189
Drug: Inhaled fentanyl aerosol
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study: NCT04713189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
Study: NCT05124912
Drug: Steroid Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical management with steroid therapy
Study: NCT04678154
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
Study: NCT04678154
Drug: Vancomycin and Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
Study: NCT05558969
Drug: pregnant women taking magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Study: NCT05558969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.